Patents by Inventor Michael Gotthardt
Michael Gotthardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101163Abstract: A rail vehicle front end has a center buffer coupling with a free coupling end section such that the free coupling end section is connectable to a further center buffer coupling of a further rail vehicle front end. The center buffer coupling extends along a longitudinal axis in a rest position. The center buffer coupling is mounted in such a way that the free coupling end section can be pivoted with respect to the longitudinal axis. The rail vehicle front end has a front panel that radially surrounds the center buffer coupling at least in sections such that a front opening pointing substantially in the longitudinal direction is defined between the front panel and the center buffer coupling. A cover device for covering the front opening extending between a front panel and a center buffer coupling of a rail vehicle is also disclosed.Type: ApplicationFiled: September 6, 2023Publication date: March 28, 2024Inventors: Michael Krug, Christopher Gotthardt, Stefan Schöppe
-
Patent number: 10118957Abstract: The invention pertains to a means for downregulating or inhibiting or mislocalizing CAR in a cardiac cell for treating/curing a patient who has suffered or is predisposed to suffering a myocardial infarction (MI) or preventing myocardial infarction or complications thereof.Type: GrantFiled: August 5, 2013Date of Patent: November 6, 2018Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Michael Gotthardt, Fabian Freiberg
-
Publication number: 20150315261Abstract: The invention pertains to a means for downregulating or inhibiting or mislocalizing CAR in a cardiac cell for treating/curing a patient who has suffered or is predisposed to suffering a myocardial infarction (MI) or preventing myocardial infarction or complications thereof.Type: ApplicationFiled: August 5, 2013Publication date: November 5, 2015Inventors: Michael Gotthardt, Fabian Freiberg
-
Patent number: 9040238Abstract: The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above.Type: GrantFiled: June 22, 2010Date of Patent: May 26, 2015Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCHInventors: Michael Gotthardt, Norbert Hübner, Marion Lewis Greaser, Wei Guo
-
Publication number: 20120277282Abstract: The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) aboveType: ApplicationFiled: June 22, 2010Publication date: November 1, 2012Applicant: MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZINInventors: Michael Gotthardt, Norbert Hübner, Marion Lewis Greaser, Wei Guo
-
Publication number: 20060242720Abstract: The present invention relates to a conditionally inducible site-directed mutant cell, comprising a mutated allele of a gene; wherein said allele comprises a mutation that was introduced by using a suitable mutagenesis technique, a rescue allele of said mutated gene that can be conditionally inactivated, wherein said mutation in said mutated allele of said gene interferes with survival and/or causes, an adverse phenotype, such as temporal and/or local phenotypes, such as cell cycle-specific, cell-type specific, tissue-specific, protein-expression specific, tissue-development specific, organ-specific, organ-development-specific and/or embryonic lethal phenotypes. According to further aspects thereof, the present invention relates to a conditionally inducible site-directed mutant cell culture, tissue, organ, or non-human embryo, comprising a cell and a respective non-human organism, in particular a genetically deficient or Knock-outmammal, -rodent, -nematode, -fish, -plant or -insect.Type: ApplicationFiled: March 4, 2004Publication date: October 26, 2006Inventors: Michael Gotthardt, Michael Radke
-
Publication number: 20060211039Abstract: The invention provides methods and compositions for inducing and detecting signal transduction through LDL receptors, including specifically detecting a stress that alters a functional interaction of a low density lipoprotein (LDL) receptor binding polypeptide with an LDL receptor interaction domain, by (a) introducing a predetermined stress into a system which provides a physical interaction of an LDL receptor binding polypeptide with an LDL receptor intracellular binding polypeptide interaction domain, whereby the system provides a stress-biased interaction of the binding polypeptide and the interaction domain, wherein the absence of the stress, the system provides a unbiased interaction of the binding polypeptide and the interaction domain; and (b) detecting the stress-biased interaction of the binding polypeptide and the interaction domain, wherein the binding polypeptide is selected from SEMCAP-1, JIP-1, PSD-95, JIP-2, Talin, OMP25, CAPON, PIP4,5 kinase, Na channel brain 3, Mint1, ICAP-1 and APC subunit1Type: ApplicationFiled: May 30, 2006Publication date: September 21, 2006Inventors: Joachim Herz, Michael Gotthardt
-
Patent number: 7056688Abstract: The invention provides methods and compositions for inducing and detecting signal transduction through LDL receptors, including specifically detecting a stress that alters a functional interaction of a low density lipoprotein (LDL) receptor binding polypeptide with an LDL receptor interaction domain, by (a) introducing a predetermined stress into a system which provides a physical interaction of an LDL receptor binding polypeptide with an LDL receptor intracellular binding polypeptide interaction domain, whereby the system provides a stress-biased interaction of the binding polypeptide and the interaction domain, wherein the absence of the stress, the system provides a unbiased interaction of the binding polypeptide and the interaction domain; and (b) detecting the stress-biased interaction of the binding polypeptide and the interaction domain, wherein the binding polypeptide is selected from SEMCAP-1, JIP-1, PSD-95, JIP-2, Talin, OMP25, CAPON, PIP4,5 kinase, Na channel brain 3, Mint1, ICAP-1 and APC subunitType: GrantFiled: August 1, 2002Date of Patent: June 6, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Joachim Herz, Michael Gotthardt
-
Publication number: 20030082640Abstract: The invention provides methods and compositions for inducing and detecting signal transduction through LDL receptors, including specifically detecting a stress that alters a functional interaction of a low density lipoprotein (LDL) receptor binding polypeptide with an LDL receptor interaction domain, by (a) introducing a predetermined stress into a system which provides a physical interaction of an LDL receptor binding polypeptide with an LDL receptor intracellular binding polypeptide interaction domain, whereby the system provides a stress-biased interaction of the binding polypeptide and the interaction domain, wherein the absence of the stress, the system provides a unbiased interaction of the binding polypeptide and the interaction domain; and (b) detecting the stress-biased interaction of the binding polypeptide and the interaction domain, wherein the binding polypeptide is selected from SEMCAP-1, JIP-1, PSD-95, JIP-2, Talin, OMP25, CAPON, PIP4,5 kinase, Na channel brain 3, Mint1, ICAP-1 and APC subunit1Type: ApplicationFiled: August 1, 2002Publication date: May 1, 2003Applicant: The University of Texas Board of RegentsInventors: Joachim Herz, Michael Gotthardt
-
Patent number: 6428967Abstract: The invention provides methods and compositions for inducing and detecting signal transduction through LDL receptors, including specifically detecting a stress that alters a functional interaction of a low density lipoprotein (LDL) receptor binding polypeptide with an LDL receptor interaction domain, by (a) introducing a predetermined stress into a system which provides a physical interaction of an LDL receptor binding polypeptide with an LDL receptor intracellular binding polypeptide interaction domain, whereby the system provides a stress-biased interaction of the binding polypeptide and the interaction domain, wherein the absence of the stress, the system provides a unbiased interaction of the binding polypeptide and the interaction domain; and (b) detecting the stress-biased interaction of the binding polypeptide and the interaction domain, wherein the binding polypeptide is selected from SEMCAP-1, JIP-1, PSD-95, JIP-2, Talin, OMP25, CAPON, PIP4,5 kinase, Na channel brain 3, Mint1, ICAP-1 and APC subunit1Type: GrantFiled: May 1, 2000Date of Patent: August 6, 2002Assignee: Board of Regents, The University of Texas SystemInventors: Joachim Herz, Michael Gotthardt